Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
August 17, 2018
Gene editing stocks, time to harvest some upside?
August 15, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
August 8, 2018
REGENXBIO (RGNX) proposes a $175 M offering
July 24, 2018
CRSPR stocks stay in the tank in another session…
July 23, 2018
CRSPR stocks stay in the tank …
July 2, 2018
MiMedx Group (MDXG) a BIG broom sweeps all...
July 2, 2018
BioLife Solutions (BLFS) reports Q2/18 – Blow-Out
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors